Evidence map›Paper›PMID 40739021›Full record

ReviewNature protocols2026

Bioink design for organ-scale projection-based 3D bioprinting.

Tianhong Qiao, Chaofan He, Pengcheng Xia, Guofeng Liu, Yuan Sun, Miao Sun, Yi Wang, Yiyu Cheng, Mengfei Yu, Yong He

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. A Systematic Review on Artificial Liver for Implantation.Journal of functional biomaterials · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tianhong QiaoState Key Laboratory of Fluid Power and Mechatronic Systems and Liangzhu Laboratory, School of Mechanical Engineering, Zhejiang University, Hangzhou, China.ORCID 0009-0009-8578-6033
Chaofan HeState Key Laboratory of Fluid Power and Mechatronic Systems and Liangzhu Laboratory, School of Mechanical Engineering, Zhejiang University, Hangzhou, China.ORCID 0000-0003-3574-7297
Pengcheng XiaDepartment of General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Guofeng LiuState Key Laboratory of Fluid Power and Mechatronic Systems and Liangzhu Laboratory, School of Mechanical Engineering, Zhejiang University, Hangzhou, China.
Yuan SunState Key Laboratory of Fluid Power and Mechatronic Systems and Liangzhu Laboratory, School of Mechanical Engineering, Zhejiang University, Hangzhou, China.
Miao SunThe Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
Yi WangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Yiyu ChengCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. chengyy@zju.edu.cn.
Mengfei YuThe Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China. yumengfei@zju.edu.cn.
Yong HeState Key Laboratory of Fluid Power and Mechatronic Systems and Liangzhu Laboratory, School of Mechanical Engineering, Zhejiang University, Hangzhou, China. yongqin@zju.edu.cn.ORCID 0000-0002-9099-0831

Funding

National Natural Science Foundation of China (National Science Foundation of China) 52235007National Natural Science Foundation of China (National Science Foundation of China) 52325504National Natural Science Foundation of China (National Science Foundation of China) T2121004Program of Zhejiang
6 · The paper itself

Abstract

Projection-based three-dimensional bioprinting offers an approach for manufacturing biomimetic tissues with complex spatial structures and bioactivity, presenting potential for creating implantable organs or organoids to test drug response. Nevertheless, the extended printing times required for organ-scale manufacturing represents a challenge. Here we provide step-by-step instructions to manufacture organ-scale structures using bioinks while preserving high bioactivity. This approach incorporates Ficoll 400 to mitigate the heterogeneity of bioink with respect to refractive index and density, while 4-(2-aminoethyl)benzenesulfonyl fluoride and oil-sealing ensure the stability of the bioink components, thereby allowing extended printing times. This procedure also enables high-cell-viability printing via the calibration of the pH value of the bioink. This Protocol is appropriate for users with basic laboratory skills and fundamental knowledge in biotechnology to manufacture organ-scale structures for utilization in a wide variety of experimental designs. The approach is generalizable, as demonstrated by the successful printing of corpora cavernosa structures with a cell density of 10 million per milliliter, measuring 10 mm × 10 mm × 10 mm. After 7 d of culture, the cell viability was measured at 82.5%, highlighting the potential applicability in tissue engineering. All bioink preparation and printing steps are expected to take 5 h, while the development of printed structures requires 7 d of continuous culture.

Indexed as

BioprintingInkPrinting, Three-DimensionalTissue EngineeringAnimalsCell SurvivalHumans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.